Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease. WSJ explains how the drug interacts with brain cells, and why some ...

A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to ...

From the beginning, the approval of its Aduhelm (aducanumab) treatment was met with controversy – over the interactions with the FDA, and the advisor committee’s vote against the treatment ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

EXTON, Pa., July 14, 2021 /PRNewswire/ — As expected with the recent media maelstrom surrounding its June 7 th approval, unaided and aided awareness of Biogen’s Aduhelm, the first disease ...

The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used ...

A Boston College Center for Retirement Research report looks at the financial implications for Medicare of Alzheimer's drug Aduhelm The recent controversy over Alzheimer’s treatment Aduhelm—criticized ...

(It’s actually the second drug shown to do this; the first one was Aduhelm.) Amyloid plaque is a substance that may lead to tissue loss in parts of the brain related to memory, thinking ...

EXTON, Pa., Sept. 16, 2021 /PRNewswire/ — The June 2021 approval of Biogen/Eisai’s Aduhelm fueled high initial expectations for the first-to-market disease-modifying therapy (DMT) for the tre ...